Biomoneta, a pioneering healthtech company building advanced air-decontamination technologies, announced that its flagship product Avata Rx, powered by its proprietary ZeBox microbicidal technology, has received approval from the United States Food and Drug Administration (US FDA), marking the first time an Indian company has achieved FDA clearance in the air-decontamination category.

This milestone is not only a validation of India’s deep-tech innovation capabilities but also reinforces the global urgency for clinically validated solutions that combat airborne pathogens, one of the most persistent sources of healthcare-associated infections (HAIs).

The approval is a major endorsement of Biomoneta’s scientific breakthrough and an important inflection point for Beyond Next Ventures India (BNV India), Japan-based early-stage deep-science fund known for backing transformative research-driven startups. BNV’s investment philosophy centers on supporting technologies rooted in deep science, real-world utility, and global scalability, and Biomoneta’s FDA recognition exemplifies this thesis.